{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:34:07Z","timestamp":1784140447148,"version":"3.55.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rupioid psoriasis is a rare subtype of psoriasis characterized by distinctive lesions resembling oyster shells, known as rupioid lesions. This subtype is particularly uncommon in the pediatric population and is often associated with poor treatment compliance. Ustekinumab, an IgG monoclonal antibody, targets IL-12 and IL-23, reducing the release of proinflammatory cytokines TNF\u03b1, IL-2, and IL-17\u03b1, which play vital roles in psoriasis pathophysiology. Approved for pediatric patients aged six years and older, ustekinumab provides a therapeutic option for moderate to severe psoriasis. We present the case of a 10-year-old girl diagnosed with psoriasis vulgaris at age two. She presented with rupioid lesions following a urinary tract infection that had been treated with oral cefixime (200\u00a0mg). After conducting appropriate tests, ustekinumab (45\u00a0mg subcutaneously) was administered, leading to significant improvements in the thickness of the lesions and overall appearance. This case demonstrates ustekinumab\u2019s efficacy in treating this challenging form of psoriasis.<\/jats:p>","DOI":"10.1093\/omcr\/omae138","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:42:03Z","timestamp":1732092123000},"source":"Crossref","is-referenced-by-count":2,"title":["Rupioid psoriasis, a unique presentation treated with Ustekinumab"],"prefix":"10.1093","volume":"2024","author":[{"given":"Sdrah","family":"Diab","sequence":"first","affiliation":[{"name":"Tishreen University Hospital Department of Dermatology and sexually transmitted disease, , Lattakia,","place":["Syria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-4125","authenticated-orcid":false,"given":"Moatasem Hussein","family":"Al-janabi","sequence":"additional","affiliation":[{"name":"Tishreen University Hospital Department of Pathology, Cancer Research Center, , Lattakia,","place":["Syria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Diab","sequence":"additional","affiliation":[{"name":"Tishreen University Hospital Department of Pediatrics, , Lattakia,","place":["Syria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouz","family":"Hassan","sequence":"additional","affiliation":[{"name":"Tishreen University Hospital Department of Dermatology, , Lattakia,","place":["Syria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2024112007581616400_ref1","doi-asserted-by":"publisher","first-page":"e26979","DOI":"10.7759\/cureus.26979","article-title":"Concomitant interstitial lung disease with psoriasis","volume":"14","author":"Kharibam","year":"2022","journal-title":"Cur\u0113us"},{"key":"2024112007581616400_ref2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1590\/abd1806-4841.20143156","article-title":"Case for diagnosis","volume":"89","author":"Antonio","year":"2014","journal-title":"An Bras Dermatol."},{"key":"2024112007581616400_ref3","first-page":"119","article-title":"Rupioid psoriasis and other skin diseases with rupioid manifestations","volume":"94","author":"Chung","year":"2014","journal-title":"Cutis"},{"key":"2024112007581616400_ref4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09546630802032611","article-title":"\u201cCoral reef\u201d psoriasis: a marker of resistance to topical treatment","volume":"19","author":"Feldman","year":"2008","journal-title":"J Dermatol Treat"},{"key":"2024112007581616400_ref5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024112007581616400_ref6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/PTT.S285832","article-title":"A successful treatment of Ostraceous psoriasis associated with psoriatic arthritis in children: a case report","volume":"Volume 10","author":"Rowawi","year":"2020","journal-title":"Psoriasis: Targets Ther"},{"key":"2024112007581616400_ref7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2014.5585","article-title":"Identification of bacterial DNA in the peripheral blood of patients with active psoriasis","volume":"151","author":"Ramirez-Bosca","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2024112007581616400_ref8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12964-023-01381-0","article-title":"Triggers for the onset and recurrence of psoriasis: a review and update","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun Signal"},{"key":"2024112007581616400_ref9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.56434\/j.arch.esp.urol.20237605.36","article-title":"Effects of Cefixime on immune functions and inflammatory factors in children with urinary tract infection and targeted nursing strategies","volume":"76","author":"Han","year":"2023","journal-title":"Arch Esp Urol"},{"key":"2024112007581616400_ref10","doi-asserted-by":"publisher","first-page":"e252500\u20130","DOI":"10.1136\/bcr-2022-252500","article-title":"Rupioid psoriasis presents with extensive hyperkeratotic plaques","volume":"16","author":"Cavazos","year":"2023","journal-title":"Case Reports"},{"key":"2024112007581616400_ref11","first-page":"23","article-title":"Ustekinumab in the treatment of severe rupioid psoriasis: a case report","volume":"19","author":"Necas","year":"2010","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"2024112007581616400_ref12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2024\/11\/omae138\/60762208\/omae138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2024\/11\/omae138\/60762208\/omae138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:42:05Z","timestamp":1732092125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omae138\/7904668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omae138","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,11,1]]},"article-number":"omae138"}}